We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s CBER Sets Its Planned Guidance Agenda for 2022
FDA’s CBER Sets Its Planned Guidance Agenda for 2022
The FDA’s Center for Biologics and Evaluation Research (CBER) put out its planned list of guidance documents it expects to release in 2022, including several that focus on gene therapies and regenerative medicines.